RYBREVANT FASPRO Shows 56% Response in HNSCC
RARITAN, N.J., Feb. 19, 2026 — Johnson & Johnson announced new Phase 1b/2 clinical data demonstrating that subcutaneous RYBREVANT...
Bispecific Antibody
Advertisement
Givastomig Phase 2 Trial Begins in Gastric Cancer
ROCKVILLE, MARYLAND, UNITED STATES — February 17, 2026 NovaBridge announced dosing of the first patient in its global, randomized...
Zenocutuzumab Gains FDA Orphan Drug Status in CCA
WALTHAM, Mass., Feb. 2026 — Partner Therapeutics announced that zenocutuzumab-zbco, an investigational bispecific antibody therapy, has received U.S. FDA...
Columvi Combo Doubles Survival in Three-Year STARGLO Results
Basel, 8 December 2025 — Roche has reported three-year follow-up findings from the pivotal phase III STARGLO study, demonstrating...
Rondo Therapeutics Begins Phase I Trial of RNDO-564 in Advanced Tumors
Dateline – San Francisco, CA – December 2025: Rondo Therapeutics has dosed the first patient in its Phase I...
Advertisements
AbbVie’s Epkinly Gets FDA Nod for Follicular Lymphoma Combo
NORTH CHICAGO, IL – November 18, 2025 — AbbVie announced that the U.S. Food and Drug Administration (FDA) has...
Novo Nordisk Submits BLA for Mim8, Offering Flexible Hemophilia A Prophylaxis
Bagsværd, Denmark & Plainsboro, N.J., September 29, 2025 – Novo Nordisk has formally submitted a Biologics License Application (BLA)...
Advertisement
